mice with smaller cell inoculums or the use of genetically engineered mice is needed.
"We need models where tumor growth is slower. We have to conduct animal studies where the cell proliferation rate is not incredibly rapid, giving the tumor time to form its normal microenvironment, with fi broblasts and endothelial cells, at a slower rate," Ellis said in a follow-up interview.
He also mentioned the importance of injecting tumors in orthotopic, or organspecifi c, locations, instead of using subcutaneous mouse models, in which tumors are injected just beneath the skin. Injecting tumors into orthotopic environments would give a much more realistic assessment of how tumors may grow in various organs that are more relevant to growth and metastasis in humans.
Furthermore, genetically engineered mouse models are needed to test different genetic backgrounds, Ellis said. "No two human tumors are built on the same genetic background," he said. He cited the pancreatic cancer model as one where the KRAS genetic mutation might be prevalent in most human tumors and serves as a good model of human cancer. But because human pancreatic cancer cells carry several disease mutations, other genetic variants should be studied in addition to KRAS-driven tumors.
With the increase in combination therapies, studying combinations in mice before doing so in humans will be important, Ellis said. At his ASCO presentation, he cited "Every time you perturb a system, the body is going to react. Sometimes these cytokines released at such levels theoretically increase tumor growth. Sometimes when we add these incredible amounts of drugs, more may not always be betterand may be worse. We are not treating HIV: Cocktails are not always better."
NEWS BRIEFS
Ellis emphasized that "we are not studying agents, but regimens," pointing to promising early-phase studies (fi rst tested in mouse models) in metastatic melanoma patients that combined a BRAF inhibitor and a MEK inhibitor. "In this new era, I hope we are smart enough to study drug combinations in vitro and in mice in vivo before we test them in humans," he said.
But conducting good experiments depends in part on creating the right research environment. The fi erce competition among young scientists to publish could compromise scientifi c integrity. At ASCO, Ellis referred to a JNCI report showing that contaminated cell lines had been used to study esophageal adenocarcinomas, which resulted in patients ' being treated with therapies that had been studied on the wrong cells in the laboratory ( see JNCI 102; . Although this example might represent the extreme, Ellis said that the competition for career advancement -and funding -is now fi ercer than ever, and that climate may lead to scientifi c slip-ups. "I think, with the 7% funding rate from NIH and people scrambling to keep careers alive, we will see massaging of data," Ellis said. "There is a lot of pressure on young scientists -and even not-so-young scientists."
Cancer Stem Cells Take Center Stage
Although some scientists have long maintained that stem cells are the seeds of cancer, clues about how to kill stem cells are just beginning to emerge. In the ASCO plenary session, Robert Weinberg, M.D., of MIT, talked about how epithelial -mesenchymal transition (EMT) is at the heart of why cancer stem cells proliferate. "EMT factors can orchestrate dissemination factors in the metastatic cascade," Weinberg said, explaining that epithelial cells that have undergone EMT can acquire stem cell properties, which allows them to seed new tumors. Weinberg cited in vitro studies of epithelial cells shown to morph into stem cells. That is why therapies need to target both stem cells and nonstem cells, Weinberg said. "We will not succeed if we are only targeting the stem cells." Ideally, targeted therapies for breast cancer stem cells would be combined with a debulking agent in the form of standard chemotherapy or an antiangiogenic agent for the other cancerous epithelial cells, according to Max Wicha, M.D., of the University of Michigan, who spoke at an ASCO panel on stem cell research. "Relapse after adjuvant therapy is a phenomenon of cancer stem cells," he said. At the same time, adjuvant trastuzumab (Herceptin) can reduce breast cancer recurrence by more than 50% in both HER2-positive and HER2-negative patients, Wicha explained. Those pivotal fi ndings, which came out of the NSABP B-31 trial and were published in the New England Journal of Medicine in 2008, revealed that the drug thought to work only on HER2-positive patients also worked on HER2-negative patients. That fi nding suggests that trastuzumab was targeting stem cells in the HER2-negative patients -because cancer stem cells do express HER2.
The recently started NSABP B-47 trial will follow up these results by testing trastuzumab in the adjuvant setting for HER2-negative women. The trial is controversial among oncologists because it fundamentally changes the original application of HER2. But Wicha is confi dent that the trial may boost support for the stem cell model, which rests, he said, on targeting "a minor population of cells, but they are the key ones."
Fight Against Cancer Goes Global
As cancer deaths around the world continue to climb -outpacing deaths from malaria, tuberculosis, and HIV/AIDS combined -international organizations are putting cancer on their agendas. With the upcoming United Nations Summit on Non-Communicable Diseases featuring cancer on September 11, "we hope to change the history of cancer," Edoardo L. Cazap, M.D., president of the Inter na tional Union on Cancer Control (UICC), told reporters at an ASCO press briefi ng. "It is extremely important to put cancer on the political agenda." Cazap said that 90% of the world ' s population cannot access new cancer treatments. Initiatives such as the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries are working to address these disparities. Taking cervical cancer as an example, Cary Adams, UICC CEO, said that cervical cancer was once the number-one killer of women in the U.S., whereas today it kills fewer than one in 100,000 women. In the developing world, however, it remains a leading cause of death in women.
ASCO also has a training course for medical oncologists, and it will send 10 -15 volunteers to Ethiopia and Vietnam. According to Allen Lichter, ASCO CEO, Ethiopia until recently had only one medical oncologist for a population of roughly 80 million people.
Old Drug, New Gold Standard
It wasn ' t the biggest story to come out of ASCO, but the data from a phase III trial showed that patients with gastrointestinal stromal tumors (GIST) cut their risk of recurrence in half after 3 years of adjuvant imatinib (Gleevec), and it had people talking.
"This is the kind of data that will change guidelines," said Mark Kris, M.D., of Memorial Sloan -Kettering Cancer Center in New York, at an ASCO press briefi ng. The Europe-based study, called SSGXVIII/AIO, included 397 patients with resected GIST in Finland, Germany, Norway, and Sweden, who took adjuvant imatinib for either 12 or 36 months. The 3-year treatment group had a 54% reduction in recurrence, a statistically signifi cant result, according to Heikki Joensuu, M.D., the 
